A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

Inclusion Criteria: * Patients with metastatic or locally advanced or unresectable GIST who have intolerance of or disease progression following prior treatment with imatinib and/or sunitinib * ECOG (Eastern Cooperative Oncology Group) performance status ≤2 * Must have measurable disease per RECIST (Response Evaluation Criteria in Solid Tumors) * Recovery from toxicity from prior therapy to Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤1 or to subject's baseline status * Adequate organ and marrow function * Sexually active subjects (male and female) must agree to use accepted methods of contraception during the course of the study and for 3 months following discontinuation of study drugs. * Female subjects of childbearing potential must have a negative pregnancy test at enrollment. Exclusion Criteria: * Therapy with imatinib or sunitinib within 14 days before the first dose of study drug * Chemotherapy, immunotherapy, targeted therapy, chemoembolization, or any investigational drug for the treatment of GIST after the last dose of imatinib or sunitinib * Anticoagulation with warfarin or coumarin-related compounds * Radiation to ≥25% of bone marrow within 28 days of study entry * Treatment with other investigational agents within 28 days of the first dose of XL820 * Known central nervous systems metastases * Uncontrolled or intercurrent illness * Pregnancy or breast-feeding * Active bacterial or viral infection requiring systemic treatment